Clinically relevant characterization of lung adenocarcinoma subtypes based on cellular pathways: an international validation study
Christopher M Bryant, Daniel L Albertus, Sinae Kim, Guoan Chen, Christian Brambilla, Mickael Guedj, Chinatsu Arima, William D Travis, Yasushi Yatabe, Takashi Takahashi, Elisabeth Brambilla, David G Beer, Christopher M Bryant, Daniel L Albertus, Sinae Kim, Guoan Chen, Christian Brambilla, Mickael Guedj, Chinatsu Arima, William D Travis, Yasushi Yatabe, Takashi Takahashi, Elisabeth Brambilla, David G Beer
Abstract
Lung adenocarcinoma (AD) represents a predominant type of lung cancer demonstrating significant morphologic and molecular heterogeneity. We sought to understand this heterogeneity by utilizing gene expression analyses of 432 AD samples and examining associations between 27 known cancer-related pathways and the AD subtype, clinical characteristics and patient survival. Unsupervised clustering of AD and gene expression enrichment analysis reveals that cell proliferation is the most important pathway separating tumors into subgroups. Further, AD with increased cell proliferation demonstrate significantly poorer outcome and an increased solid AD subtype component. Additionally, we find that tumors with any solid component have decreased survival as compared to tumors without a solid component. These results lead to the potential to use a relatively simple pathological examination of a tumor in order to determine its aggressiveness and the patient's prognosis. Additional results suggest the ability to use a similar approach to determine a patient's sensitivity to targeted treatment. We then demonstrated the consistency of these findings using two independent AD cohorts from Asia (N = 87) and Europe (N = 89) using the identical analytic procedures.
Conflict of interest statement
Competing Interests: The authors have declared that no competing interests exist.
Figures
References
- Jemal A, Thun MJ, Ries LA, Howe HL, Weir HK, et al. Annual report to the nation on the status of cancer, 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Inst. 2008;100:1672–1694.
- Jemal A, Clegg LX, Ward E, Ries LA, Wu X, et al. Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival. Cancer. 2004;101:3–27.
- Shedden K, Taylor JM, Enkemann SA, Tsao MS, Yeatman TJ, et al. Director's Challenge Consortium for the Molecular Classification of Lung Adenocarcinoma. Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med. 2008;14:822–827.
- Weir BA, Woo MS, Getz G, Perner S, Ding L, et al. Characterizing the cancer genome in lung adenocarcinoma. Nature. 2007;450:893–898.
- Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature. 2008;455:1069–1075.
- Motoi N, Szoke J, Riely GJ, Seshan VE, Kris MG, et al. Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis. Am J Surg Pathol. 2008;32:810–827.
- Travis WD. Pathology of lung cancer. Clin Chest Med. 2002;23:65–81.
- Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA. 1998;95:14863–14868.
- Ben-Porath I, Thomson MW, Carey VJ, Ge R, Bell GW, et al. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet. 2008;40:499–507.
- Takeuchi T, Tomida S, Yatabe Y, Kosaka T, Osada H, et al. Expression profile-defined classification of lung adenocarcinoma shows close relationship with underlying major genetic changes and clinicopathologic behaviors. J Clin Oncol. 2006;24:1679–1688.
- Brambilla (in press)
- Beer DG, Kardia SL, Huang CC, Giordano TJ, Levin AM, et al. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med. 2002;8:816–824.
- Garber ME, Troyanskaya OG, Schluens K, Petersen S, Thaesler Z, et al. Diversity of gene expression in adenocarcinoma of the lung. Proc Natl Acad Sci U S A. 2001;98:13784–13789.
- Pepicelli CV, Lewis PM, McMahon AP. Sonic hedgehog regulates branching morphogenesis in the mammalian lung. Curr Biol. 1998;8:1083–1086.
- Ebi H, Tomida S, Takeuchi T, Arima C, Sato T, et al. Relationship of deregulated signaling converging onto mTOR with prognosis and classification of lung adenocarcinoma shown by two independent in silico analyses. Cancer Res. 2009;69:4027–4035.
Source: PubMed